Studie TRIO-022 (A5481008)

TRIO-022 (A5481008)

A Randomized, Multicenter, Doube-blind Phase III Study of PD 0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER(+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease

Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany

III

Rekrutierung beendet

Unbekannt / Unbekannt

1

Hormon,Zielgerichtet - Therapieart: palliativ